JP2010539974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539974A5 JP2010539974A5 JP2010527904A JP2010527904A JP2010539974A5 JP 2010539974 A5 JP2010539974 A5 JP 2010539974A5 JP 2010527904 A JP2010527904 A JP 2010527904A JP 2010527904 A JP2010527904 A JP 2010527904A JP 2010539974 A5 JP2010539974 A5 JP 2010539974A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- reducing
- inhibiting
- administered
- oligonucleotide compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 7
- 230000001603 reducing effect Effects 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 230000005012 migration Effects 0.000 claims 5
- 238000013508 migration Methods 0.000 claims 5
- 206010030113 Oedema Diseases 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010044541 Traumatic shock Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 210000003722 extracellular fluid Anatomy 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000008728 vascular permeability Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97801007P | 2007-10-05 | 2007-10-05 | |
| US60/978,010 | 2007-10-05 | ||
| PCT/SE2008/000542 WO2009045145A1 (en) | 2007-10-05 | 2008-10-02 | Novel compounds for the treatment or alleviation of edema, and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014101486A Division JP5914567B2 (ja) | 2007-10-05 | 2014-05-15 | 浮腫を治療または軽減するための新規な化合物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539974A JP2010539974A (ja) | 2010-12-24 |
| JP2010539974A5 true JP2010539974A5 (enExample) | 2011-11-10 |
| JP5547637B2 JP5547637B2 (ja) | 2014-07-16 |
Family
ID=40526448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010527904A Expired - Fee Related JP5547637B2 (ja) | 2007-10-05 | 2008-10-02 | 浮腫を治療または軽減するための新規な化合物およびその使用方法 |
| JP2014101486A Expired - Fee Related JP5914567B2 (ja) | 2007-10-05 | 2014-05-15 | 浮腫を治療または軽減するための新規な化合物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014101486A Expired - Fee Related JP5914567B2 (ja) | 2007-10-05 | 2014-05-15 | 浮腫を治療または軽減するための新規な化合物およびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8410068B2 (enExample) |
| EP (2) | EP2656850B1 (enExample) |
| JP (2) | JP5547637B2 (enExample) |
| CA (1) | CA2738070C (enExample) |
| DK (1) | DK2656850T3 (enExample) |
| ES (1) | ES2600919T3 (enExample) |
| WO (1) | WO2009045145A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8309529B2 (en) * | 2007-05-04 | 2012-11-13 | Index Pharmaceuticals Ab | Tumour growth inhibitory compounds and methods of their use |
| US20110182880A1 (en) * | 2008-06-18 | 2011-07-28 | Oliver Von Stein | Combination Therapies Against Cancer |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| AU2009311753B2 (en) | 2008-11-04 | 2015-01-15 | Index Pharmaceuticals Ab | Compounds and methods for the treatment of inflammatory diseases of the CNS |
| US9157919B2 (en) * | 2010-12-21 | 2015-10-13 | Index Pharmaceuticals Ab | Method for identifying biologically active oligonucleotides capable of modulating the immune system |
| WO2012084991A1 (en) * | 2010-12-21 | 2012-06-28 | Index Pharmaceuticals Ab | Biologically active oligonucleotides capable of modulating the immune system ii |
| PL2731597T3 (pl) * | 2011-07-12 | 2024-04-29 | Vanderbilt University | Sposoby leczenia stanu zapalnego i nadciśnienia tętniczego za pomocą wychwytywaczy gamma-ketoaldehydowych |
| GB201707501D0 (en) * | 2017-05-10 | 2017-06-21 | Index Pharmaceuticals Ab | New therapy 2 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610289A (en) * | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| DE69232722T2 (de) * | 1991-08-23 | 2002-12-05 | The Board Of Regents Of The University Of Nebraska, Lincoln | Verfahren und zusammensetzungen für zelluläre reprogrammierung |
| US7517644B1 (en) * | 1991-08-23 | 2009-04-14 | Larry J. Smith | Method and compositions for cellular reprogramming |
| US5968826A (en) * | 1998-10-05 | 1999-10-19 | Isis Pharmaceuticals Inc. | Antisense inhibition of integrin α4 expression |
| US6610836B1 (en) * | 1999-01-29 | 2003-08-26 | Genome Therapeutics Corporation | Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| WO2002012894A1 (en) * | 2000-08-09 | 2002-02-14 | Mount Sinai School Of Medicine | Kruppel-like factor 6 (klf6), a tumorsuppressor protein, and dia gnostics, therapeutics, and screening based on this protein |
| US7630836B2 (en) * | 2001-05-30 | 2009-12-08 | The Kitasato Institute | Polynucleotides |
| AU2003303305A1 (en) * | 2002-10-02 | 2004-09-30 | Nuvelo,Inc. | Novel nucleic acids and polypeptides |
| AU2003271725A1 (en) * | 2002-10-15 | 2004-05-04 | Novartis Ag | Methods to predict edema as a side effect of drug treatment |
| JP2004166699A (ja) * | 2002-11-06 | 2004-06-17 | Takeda Chem Ind Ltd | 抗利尿剤 |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| WO2005033284A2 (en) * | 2003-10-01 | 2005-04-14 | The Regents Of The University Of California | Compositions and methods for gene expression |
| US7374927B2 (en) * | 2004-05-03 | 2008-05-20 | Affymetrix, Inc. | Methods of analysis of degraded nucleic acid samples |
| DK2179737T3 (da) * | 2005-07-01 | 2013-11-11 | Index Pharmaceuticals Ab | Modulering af respons på steroider |
| CA2618081A1 (en) * | 2005-08-09 | 2007-02-15 | University Of Virginia Patent Foundation | Methods and compositions for inhibition of vascular permeability |
| US8309529B2 (en) * | 2007-05-04 | 2012-11-13 | Index Pharmaceuticals Ab | Tumour growth inhibitory compounds and methods of their use |
-
2008
- 2008-10-02 EP EP13177620.5A patent/EP2656850B1/en not_active Not-in-force
- 2008-10-02 JP JP2010527904A patent/JP5547637B2/ja not_active Expired - Fee Related
- 2008-10-02 DK DK13177620.5T patent/DK2656850T3/en active
- 2008-10-02 US US12/681,590 patent/US8410068B2/en not_active Expired - Fee Related
- 2008-10-02 CA CA2738070A patent/CA2738070C/en not_active Expired - Fee Related
- 2008-10-02 EP EP08835591.2A patent/EP2207555B1/en not_active Not-in-force
- 2008-10-02 WO PCT/SE2008/000542 patent/WO2009045145A1/en not_active Ceased
- 2008-10-02 ES ES13177620.5T patent/ES2600919T3/es active Active
-
2014
- 2014-05-15 JP JP2014101486A patent/JP5914567B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539974A5 (enExample) | ||
| WO2009044392A3 (en) | Novel sirna structures | |
| JP2015519891A5 (enExample) | ||
| RU2018125514A (ru) | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента | |
| JP2011528333A5 (enExample) | ||
| JP2010519383A5 (enExample) | ||
| WO2008100867A3 (en) | Novel inhibitors hepatitis c virus replication | |
| WO2007122580A3 (en) | Compositions of phenylephrine useful for treatment of respiratory illness | |
| JP2014518275A5 (enExample) | ||
| MX373926B (es) | Metodos para tratar cancer y estados no neoplasicos. | |
| JP2011511786A5 (enExample) | ||
| ATE395905T1 (de) | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs | |
| ATE455776T1 (de) | Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns | |
| JP2016510326A5 (enExample) | ||
| JP2015514778A5 (enExample) | ||
| JP2009508822A5 (enExample) | ||
| JP2009543800A5 (enExample) | ||
| JP2012503669A5 (enExample) | ||
| JP2009534451A5 (enExample) | ||
| WO2010049709A3 (en) | Therapeutic compositions comprising phenolic acids for treating conditions related to inap proriate platelet aggregation | |
| EP2106260A4 (en) | INSULIN SENSITIZERS AND TREATMENT PROCEDURES THEREWITH | |
| WO2011153458A3 (en) | Compositions and methods for inhibition of or treatment of dengue virus infection | |
| MX2007013876A (es) | Uso de inhibidor de la via del factor de tejido para tratar infecciones bacterianas severas. | |
| WO2008073466A3 (en) | Alpha b-crystallin as a therapy for inflammation | |
| AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa |